INTEGRA LIFESCIENCES HOLDINGS CORPIART财报
Integra LifeSciences Holdings Corporation is a global medical device manufacturing company headquartered in Princeton, New Jersey. Founded in 1989, the company manufactures products for skin regeneration, neurosurgery, reconstructive and general surgery. Integra artificial skin became the first commercially reproducible skin tissue used to treat severe burns and other skin wounds.
IART Q4 2025 Key Financial Metrics
营收
$434.9M
毛利润
$220.9M
营业利润
$23.0M
净利润
N/A
毛利率
50.8%
营业利润率
5.3%
净利率
N/A
同比增长
-1.7%
EPS
$-0.03
资金流向
INTEGRA LIFESCIENCES HOLDINGS CORP Q4 2025 财务摘要
INTEGRA LIFESCIENCES HOLDINGS CORP reported revenue of $434.9M (down 1.7% YoY) for Q4 2025, with a net profit of N/A (N/A margin). Cost of goods sold was $214.1M, operating expenses totaled $197.8M.
核心财务指标
| 总营收 | $434.9M |
|---|---|
| 净利润 | N/A |
| 毛利率 | 50.8% |
| 营业利润率 | 5.3% |
| 报告期 | Q4 2025 |
营收拆解
INTEGRA LIFESCIENCES HOLDINGS CORP Q4 2025 revenue of $434.9M breaks down across 6 segments, led by Neurosurgery at $226.2M (52.0% of total).
| 业务分部 | 营收 | 占比 |
|---|---|---|
| Neurosurgery | $226.2M | 52.0% |
| Asia Pacific | $53.7M | 12.4% |
| Instruments | $52.3M | 12.0% |
| ENT | $44.8M | 10.3% |
| Other | $38.9M | 8.9% |
| Rest Of The World | $19.0M | 4.4% |
INTEGRA LIFESCIENCES HOLDINGS CORP 分部营收 — 季度趋势
INTEGRA LIFESCIENCES HOLDINGS CORP revenue by segment across the last 4 reported quarters, showing how each business line (such as Neurosurgery and Asia Pacific) has evolved quarter over quarter.
| 业务分部 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|
| Neurosurgery | $226.2M | $201.6M | $209.0M | $190.9M |
| Asia Pacific | $53.7M | $42.7M | $47.7M | $45.1M |
| Instruments | $52.3M | $50.2M | $53.1M | — |
| ENT | $44.8M | — | $41.9M | $38.8M |
| Other | $38.9M | — | $44.9M | $31.5M |
INTEGRA LIFESCIENCES HOLDINGS CORP 年度营收
INTEGRA LIFESCIENCES HOLDINGS CORP annual revenue history includes year-by-year totals (for example, 2025 revenue was $1.6B). Click any linked year to see what changed vs the prior 10-K.
INTEGRA LIFESCIENCES HOLDINGS CORP 季度营收与净利润历史
INTEGRA LIFESCIENCES HOLDINGS CORP quarterly results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| 季度 | 营收 | 营收同比 | 净利润 | 净利率 |
|---|---|---|---|---|
| Q4 2025 | $434.9M | -1.7% | N/A | N/A |
| Q3 2025 | $402.1M | +5.6% | $-5.4M | -1.3% |
| Q2 2025 | $415.6M | -0.6% | $-484.1M | -116.5% |
| Q1 2025 | $382.7M | +3.7% | $-25.3M | -6.6% |
| Q4 2024 | $442.6M | +11.5% | N/A | N/A |
| Q3 2024 | $380.8M | -0.4% | $-10.7M | -2.8% |
| Q2 2024 | $418.2M | +9.7% | $-12.4M | -3.0% |
| Q1 2024 | $368.9M | -3.1% | $-3.3M | -0.9% |
利润表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 营收 | $368.9M | $418.2M | $380.8M | $442.6M | $382.7M | $415.6M | $402.1M | $434.9M |
| 同比增长 | -3.1% | 9.7% | -0.4% | 11.5% | 3.7% | -0.6% | 5.6% | -1.7% |
资产负债表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 总资产 | $4.08B | $4.07B | $4.07B | $4.04B | $4.05B | $3.67B | $3.65B | $3.60B |
| 总负债 | $2.48B | $2.54B | $2.54B | $2.49B | $2.53B | $2.63B | $2.61B | $2.56B |
| 股东权益 | $1.60B | $1.53B | $1.52B | $1.55B | $1.52B | $1.04B | $1.04B | $1.04B |
现金流量表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 经营性现金流 | $15.8M | $40.4M | $22.5M | $50.7M | $-11.3M | $8.9M | $40.9M | $11.8M |